ECSP11011373A - Agentes terapeúticos inmunomoduladores - Google Patents
Agentes terapeúticos inmunomoduladoresInfo
- Publication number
- ECSP11011373A ECSP11011373A EC2011011373A ECSP11011373A ECSP11011373A EC SP11011373 A ECSP11011373 A EC SP11011373A EC 2011011373 A EC2011011373 A EC 2011011373A EC SP11011373 A ECSP11011373 A EC SP11011373A EC SP11011373 A ECSP11011373 A EC SP11011373A
- Authority
- EC
- Ecuador
- Prior art keywords
- symptoms
- improving
- peptides
- fibrinopeptide
- decreasing
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 208000024891 symptom Diseases 0.000 abstract 3
- 108010073385 Fibrin Proteins 0.000 abstract 2
- 102000009123 Fibrin Human genes 0.000 abstract 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 2
- 101800000974 Fibrinopeptide A Proteins 0.000 abstract 2
- 101800003778 Fibrinopeptide B Proteins 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000008021 deposition Effects 0.000 abstract 2
- 229950003499 fibrin Drugs 0.000 abstract 2
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 102000016918 Complement C3 Human genes 0.000 abstract 1
- 108010028780 Complement C3 Proteins 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 102400000525 Fibrinopeptide A Human genes 0.000 abstract 1
- 102400001063 Fibrinopeptide B Human genes 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000022371 chronic pain syndrome Diseases 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15852609P | 2009-03-09 | 2009-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011373A true ECSP11011373A (es) | 2011-11-30 |
Family
ID=42729052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011373A ECSP11011373A (es) | 2009-03-09 | 2011-10-04 | Agentes terapeúticos inmunomoduladores |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110318375A1 (https=) |
| EP (1) | EP2405935A2 (https=) |
| JP (1) | JP2012520306A (https=) |
| KR (1) | KR20120008029A (https=) |
| CN (1) | CN102439175A (https=) |
| AU (1) | AU2010222851A1 (https=) |
| BR (1) | BRPI1009569A2 (https=) |
| CA (1) | CA2753871A1 (https=) |
| EC (1) | ECSP11011373A (https=) |
| MX (1) | MX2011009475A (https=) |
| RU (1) | RU2011137856A (https=) |
| SG (1) | SG174290A1 (https=) |
| WO (1) | WO2010104854A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104837358B (zh) | 2012-12-14 | 2019-03-29 | 希尔氏宠物营养品公司 | 用于陪伴动物的抗衰老食物 |
| EP3439683A4 (en) * | 2016-04-04 | 2020-07-29 | Marpe Holdings, LLC | MODULATION OF THE IMMUNE SYSTEM FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS |
| JP2018163071A (ja) * | 2017-03-27 | 2018-10-18 | 京都府公立大学法人 | 関節リウマチに関するペプチドマーカー |
| CN110045130B (zh) * | 2019-04-17 | 2022-03-29 | 中山大学附属第一医院 | 一种与IgA肾病相关的多肽的免疫分析检测试剂盒 |
| WO2025017038A2 (en) * | 2023-07-17 | 2025-01-23 | Angus Dalgleish | Serum-derived peptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673561B1 (en) * | 1999-06-30 | 2004-01-06 | Regents Of The University Of California | Diagnostic test for thrombotic or thromboembolic disease |
| WO2003065997A2 (en) * | 2002-02-06 | 2003-08-14 | Vicor Technologies, Inc. | Anti-infarction molecules |
| US20080294261A1 (en) * | 2007-05-24 | 2008-11-27 | Kevin Pauza | Method for treating herniated discs |
-
2010
- 2010-03-09 WO PCT/US2010/026665 patent/WO2010104854A2/en not_active Ceased
- 2010-03-09 AU AU2010222851A patent/AU2010222851A1/en not_active Abandoned
- 2010-03-09 CA CA2753871A patent/CA2753871A1/en not_active Abandoned
- 2010-03-09 KR KR1020117023511A patent/KR20120008029A/ko not_active Ceased
- 2010-03-09 JP JP2011554122A patent/JP2012520306A/ja not_active Withdrawn
- 2010-03-09 BR BRPI1009569A patent/BRPI1009569A2/pt not_active Application Discontinuation
- 2010-03-09 SG SG2011064581A patent/SG174290A1/en unknown
- 2010-03-09 CN CN2010800203608A patent/CN102439175A/zh active Pending
- 2010-03-09 RU RU2011137856/15A patent/RU2011137856A/ru not_active Application Discontinuation
- 2010-03-09 EP EP10751287A patent/EP2405935A2/en not_active Withdrawn
- 2010-03-09 MX MX2011009475A patent/MX2011009475A/es not_active Application Discontinuation
- 2010-03-09 US US13/203,045 patent/US20110318375A1/en not_active Abandoned
-
2011
- 2011-10-04 EC EC2011011373A patent/ECSP11011373A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011137856A (ru) | 2013-04-20 |
| CA2753871A1 (en) | 2010-09-16 |
| KR20120008029A (ko) | 2012-01-25 |
| SG174290A1 (en) | 2011-10-28 |
| WO2010104854A3 (en) | 2010-11-04 |
| BRPI1009569A2 (https=) | 2016-03-22 |
| AU2010222851A1 (en) | 2011-09-15 |
| US20110318375A1 (en) | 2011-12-29 |
| EP2405935A2 (en) | 2012-01-18 |
| CN102439175A (zh) | 2012-05-02 |
| JP2012520306A (ja) | 2012-09-06 |
| MX2011009475A (es) | 2011-12-08 |
| WO2010104854A2 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011373A (es) | Agentes terapeúticos inmunomoduladores | |
| EA200900098A1 (ru) | Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов | |
| CY1123690T1 (el) | Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων | |
| CL2015001241A1 (es) | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) | |
| MX391624B (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| EA201190338A1 (ru) | Пептиды, специфичные к меланокортиновым рецепторам | |
| MX373788B (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 especifica de ubiquitina. | |
| EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
| EA201892339A2 (ru) | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания | |
| EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
| EA201791768A1 (ru) | Иммуномодулирующие агенты | |
| UY33206A (es) | Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4 | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| WO2015086406A3 (en) | Factor ix variants with clotting activity in absence of their cofactor and/or with increased f.ix clotting activity and their use for treating bleeding disorders | |
| EA201001722A1 (ru) | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции | |
| EA201491081A1 (ru) | Композиции и способы для лечения заболеваний и расстройств печени | |
| CO2023005057A2 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
| WO2014116097A3 (es) | Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox | |
| CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| EA201391387A1 (ru) | Нейропротекторные пептиды | |
| EA201100605A1 (ru) | Комбинированная терапия, включающая ингибитор dhodh и метотрексат, для лечения аутоиммунного заболевания | |
| WO2011115456A3 (ko) | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 | |
| EP4007588C0 (en) | PLANT EXOSOMES USED FOR THE TREATMENT OF DISEASES RESULTING FROM PROTEIN AGGREGATES FORMED IN CELLS | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита |